A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 164 participants.

Also called NCT06664801

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 164 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06664801
  • EU CT 2024-512278-92-00
  • WHO UTN U1111-1304-7985
  • jRCT jRCT2061240077
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Australia, Canada, China, Colombia, Czechia, France, Germany, Hungary, Israel, Italy, Japan, Netherlands, Poland, Singapore, South Korea, Spain, Taiwan, Thailand, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06664801. Randomized; single masking; primary purpose treatment. Start 2024-11-14 (actual); primary completion 2025-11-20 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)
Acronym
LIGHTRAY
Condition
Pulmonary Arterial Hypertension
Intervention (Biological)
Sotatercept
Intervention (Biological)
Background PAH Therapy
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct06664801
Content hash
053dc07485676b74a63d78a701a350e15ecc445e1800a9ab66e2875f3e32ad99